CV
Therapeutic Areas
Lundbeck Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rexulti (brexpiprazole) | Major Depressive Disorder (adjunct), Schizophrenia | Approved/Commercial |
| Vyepti (eptinezumab) | Migraine prevention | Approved/Commercial |
| Trintellix/Brintellix (vortioxetine) | Major Depressive Disorder | Approved/Commercial |
| Sabril (vigabatrin) | Refractory Complex Partial Seizures, Infantile Spasms | Approved/Commercial |
| Abilify Maintena (aripiprazole) | Schizophrenia, Bipolar I Disorder | Approved/Commercial |
| Lu AG09222 (PACAP mAb) | Migraine prevention | Phase 2 |
| Lu AG06466 (MAT2A Inhibitor) | Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) | Phase 1/2 |
| Lu AG13909 (PDE10A Inhibitor) | Schizophrenia | Phase 1 |
Leadership Team at Lundbeck
TG
Thomas Gibbs
Executive Vice President and President
DD
Deborah Dunsire
President and Chief Executive Officer
JL
Johan Luthman
Executive Vice President, Head of Research & Development
AG
Anders Götzsche
Executive Vice President, Chief Financial Officer
SJ
Steen Juul Jensen
Executive Vice President, Chief Medical Officer
AK
Anne-Marie K. K. Ehrlich
Executive Vice President, People & Organization
BS
Berit Scheel
Executive Vice President, Head of Legal, Compliance & Sustainability
JK
Judy Krieg
Account Manager
RS
Ronetta Stokes
Person living with migraine
M
Margot
Person living with chronic migraine